Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
06/18ALLERGAN : Continues Active Board Refreshment Process
AQ
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR I..
AQ
06/14ALLERGAN : Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients..
AQ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14ALLERGAN : Continues Active Board Refreshment Process
PR
06/13ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (..
PR
06/13ALLERGAN : Lawsuit Filed Against Allergan for Defectively Packaged Taytulla&trad..
AQ
06/13ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
AQ
06/12ALLERGAN : and Actress Shay Mitchell Join Forces to Inspire Women to Know Their ..
AQ
More news
Financials ($)
Sales 2018 15 289 M
EBIT 2018 7 368 M
Net income 2018 -1 127 M
Debt 2018 23 406 M
Yield 2018 1,60%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,37x
EV / Sales 2019 5,06x
Capitalization 58 719 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 206 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC58 719
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880